Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below:
New York, NY
- Tweets 1,250
- Following 195
- Followers 14,701
- Likes 148
Join Dr. Yatham and Dr. Vieta at #ISBD2026 as they discuss the current treatment landscape, unmet needs, hypothesized disease mechanisms, emerging therapies and advances toward personalized management.
1
169
During #IMS26, Dr. Doris Hansen will present results from a Phase 1 study focused on an investigational dual-targeting CAR T cell therapy approach being evaluated in patients with relapsed/refractory multiple myeloma.
See our latest research updates: bit.ly/3UXV7gh
1
176
Our diverse portfolio is designed to bridge critical gaps in myeloma care with innovative options for a broad range of patients. At #IMS26, we’re sharing the latest breakthroughs shaping the future of care.
156
Join us at #IMS26 on Friday, September 25, for an oral presentation exploring the Phase 3 EXCALIBER-RRMM results.
Explore our latest hematology research updates: bit.ly/47eRgOr
1
2
221
We’re excited to be at this year’s #IMS26, showcasing the advances we’re making across protein degradation and cell therapy platforms to strengthen our approach for multiple myeloma treatment at every step of the journey.
1
1
193
Today at #IMS26, we're sharing Phase 3 research evaluating hematologic adverse events and infections associated with treatment, as well as health-related quality of life, in relapsed/refractory multiple myeloma.
See more on our hematology research: bit.ly/4yRSTxA
1
1
294
OUT NOW: A special 2-part episode of #DoctoRxUnscripted! Dr. Tania Small, Chris Boerner, @ariannahuff and Dr. @Neil_Iyengar explore how precision oncology & behavioral science unite to transform patient outcomes. Watch: bit.ly/3V8UTmp
1
4
234
At #IMS26 we’ll be presenting our latest updates in multiple myeloma, including advances from our protein degradation platform and research spanning our multiple myeloma portfolio and pipeline, including CAR T cell therapy.
Explore our research: bit.ly/4d0c3c2
2
185
Join us at #ENGAGE26 as Susan Scanland, a geriatric nurse practitioner, explores the unmet needs and evidence-based management of psychosis and agitation in Alzheimer’s disease. Gain practical strategies for symptom assessment, care partner engagement and shared decision-making.
1
112
Join us at #PsychCongress2026 for two Medical Innovation Theater sessions exploring the evolving understanding of schizophrenia and bipolar I disorder.
Learn more about our medical events and scientific exchange opportunities: bit.ly/3UKE01l
#OneBMS
1
195
Join us at #PsychCongress2026 as Dr. Tohen explores the diagnostic challenges in bipolar disorder, examines real-world evidence to deepen understanding of disease course, and discusses the evolving research landscape around long-term outcomes.
168
At #WCLC2026, we're sharing updates from studies evaluating an investigational bispecific in NSCLC and mesothelioma. Hear from Rajni Kannan on how scientific exchange and collaboration inform our work as we advance the bispecific research platform. bit.ly/3UVBg12 #OneBMS
1
3
7
556
As the biomarker landscape continues to evolve, comprehensive testing is an important part of identifying patients. Join us at #ECP2026 as we discuss practical considerations & emerging approaches in NSCLC diagnostics.
Explore the latest on MTAP deletion: bit.ly/4xLcWgQ
2
178
From clinical trial insights to real-world evidence, we’ll be presenting exciting updates on our immuno-oncology research across tumor types at #WCLC26.
Hear more from Pratik Thakkar and stop by our booth to connect with our team in Seoul. bit.ly/4xLIiE9
#OneBMS
2
7
271
Join us at #WCLC26 as @LuisPaz_Ares and @DrMarkAwad present the ROSETTA Lung-201 and ROSETTA Lung-202 Trial-in-Progress (TiP) posters, highlighting new data in non-small cell lung cancer. Explore our oncology research updates: bit.ly/4cBuO5p #OneBMS #BioNTech_Group
1
1
324
Join us at #PsychCongress2026 as Dr. Christoph Correll and Andrew Penn explore the evolving understanding of schizophrenia pathophysiology, describe the current treatment landscape and discuss pathways that could inform the direction of future research.
223
Join us tomorrow at #WCLC2026 for a mini-oral presentation featuring long-term PFS and OS data investigating a PD-L1xVEGF-A bispecific antibody in mesothelioma.
Explore our latest oncology research updates: bit.ly/3VaHLgx
#OneBMS #Mesothelioma #BioNTech_Group
1
229
We're working to advance research for people with homozygous MTAP deletions, a biomarker found in some solid tumors that remains underrecognized in routine testing. Explore MTAP Matters, a new resource on the latest in MTAP deletion research: bit.ly/4xpsjuy
#ECP2026
1
3
204
Hear from Shreya Mitra about one of the studies our team will present at #WCLC26 on the potential of antibody-drug conjugates (ADCs). Visit the BMS Grand Medical Library to learn more about our science. Explore our latest oncology research updates: bit.ly/3ULc6lL #OneBMS
3
211
Today’s official #WCLC2026 press program featured results from our global Phase 1 randomized dose-expansion study in previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Join us for the full presentation on Sept. 14.
Learn more: bit.ly/4xPCERi
#OneBMS
228